Genentech, Inc.

Aurigene Discovery Technologies Limited

Debiopharm S.a.

Enzo Therapeutics, Inc.

Enzo Life Sciences, Inc.

University of Geneva

Enzo Life Sciences (els) Ag

Maximilien Murone

Arnon Rosenthal

Frederic J De Sauvage

Austin L Gurney

William I Wood

Saumitra Sengupta

Donna Marie Stone

Andrès Mc Allister

Shankar Jayaram Shetty

Bertrand Huard

Lars French

Olivier Donze

Olivier Donzé

The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3. 

Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors

The invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2), in particular the monoclonal antibody Aprily-2, hybridoma cells producing monoclonal antibody Aprily-2, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2 in the diagnosis of B cell lymphoma resistance to treatment and the prognosis of clinical development of Diffuse Large B-Cell (DLBCL) lymphoma from high risk patients (&#x3e;60 years and International Prognostic Index &#x3e;2). An amino acid sequence GTGGPSQNGEGYP called Stalk, useful in the preparation of antibodies, is described.

Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients

Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors

The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.

Nucleic acid encoding fused

The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of thefused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Assay methods for suppressor of fused modulation of hedgehog signaling

Anti-fused antibodies

The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of themelanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Nucleic acid encoding human suppressor of fused

The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptide, vectors and host cells expressing, immunoadhesins, agonists and antagonists to human & vertebrate fused.

Fused polypeptides

Growing community of inventors

Epalinges, Switzerland

Maximilien Murone